ChemoCentryx
Develops orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractants.
Launch date
Employees
Market cap
AUD5.8b
Enterprise valuation
AUD5.4b (Public information from Nov 2022)
Share price
$51.99 CCXI
San Carlos California (HQ)
Authorizing premium user...